格隆汇11月12日丨北大医药(000788.SZ)公布，公司于近日经有关部门核实，获悉公司董事长、总裁徐 晰人先生因涉嫌刑事犯罪，已被重庆市江北区人民检察院批准逮捕。截至本公告披露日，公司董事陈岳 忠先生根据授权代为行使董事长职责，公司常务副总裁余孟川先生根据授权代为行使总裁及法定代表人 职责。公司控制权未发生变化，公司董事会运作正常，公司财务及生产经营管理情况正常。 ...

（文章来源：第一财经） 北大医药晚间公告，公司董事长、总裁徐晰人因涉嫌刑事犯罪已被重庆市江北区人民检察院批准逮捕。 此前公司于2025年10月25日、10月30日披露了徐晰人因被刑事拘留暂时无法正常履职的情况。 公告显示，目前公司董事陈岳忠根据授权代为行使董事长职责，常务副总裁余孟川根据授权代为行使总 裁及法定代表人职责。公司强调控制权未发生变化，董事会运作正常，公司财务及生产经营管理情况正 常。 ...

Core Points - The chairman and president of Beijing University Pharmaceutical (000788) has been arrested for suspected criminal activity [1] - The company's board operations remain normal, and there has been no change in control [1] - The company will continue to fulfill its information disclosure obligations [1] Company Management - Xu Xiren, the chairman and president, has been replaced by director Chen Yuezhong as acting chairman [1] - Executive vice president Yu Mengchuan will serve as acting president and legal representative [1] Operational Status - The company's financial and operational management remains normal despite the leadership changes [1]

公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券日报》《证 券时报》及巨潮资讯网（http://www.cninfo.com.cn），公司所有信息均以在上 述指定媒体披露的信息为准，敬请广大投资者注意投资风险。 特此公告。 北大医药股份有限公司 关于公司董事长、总裁暂时无法正常履职的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于2025年10月25日、2025年10 月30日在巨潮资讯网分别披露了《关于公司董事长、总裁授权公司董事代行董事 长职责、授权公司常务副总裁代行总裁及法定代表人职责的公告》（公告编号： 2025-078）、《关于公司董事长、总裁暂时无法正常履职的进展公告》（公告编 号：2025-079）。公司董事长、总裁徐晰人先生因被刑事拘留，暂时无法正常履 职，授权公司董事陈岳忠先生代为行使董事长职责，授权公司常务副总裁余孟川 先生代为行使总裁及法定代表人职责。 公司于近日经有关部门核实，获悉公司董事长、总裁徐晰人先生因涉嫌刑事 犯罪，已被重庆市江北区人民检察院批准逮捕。 截至本公告披露 ...

关于持股 5%以上股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于近日收到持股5%以上股东北大 医疗管理有限责任公司（以下简称"北大医疗"）的通知，获悉北大医疗持有的公 司部分股份办理了解除质押手续。现将相关情况公告如下： 一、股东所持公司部分股份解除质押基本情况 | 股东名称 | 是否为控股 股东或第一 大股东及其 一致行动人 | 本次解除质押 股份数量（股） | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 北大医疗管理有限 责任公司 | 否 | 34,615,386 | 51.52% | 5.81% | 2024-04-28 | 2025-11-11 | 中国银行 股份有限 公司深圳 东门支行 | | 合计 | - | 34,615,386 | 51.52% | 5.81% | - | - | - | 1、本次股份解除质押基本情况 2、股东股份 ...

格隆汇11月12日丨北大医药(000788.SZ)公布，公司于近日经有关部门核实，获悉公司董事长、总裁徐 晰人先生因涉嫌刑事犯罪，已被重庆市江北区人民检察院批准逮捕。截至本公告披露日，公司董事陈岳 忠先生根据授权代为行使董事长职责，公司常务副总裁余孟川先生根据授权代为行使总裁及法定代表人 职责。公司控制权未发生变化，公司董事会运作正常，公司财务及生产经营管理情况正常。 ...

Market Performance - The pharmaceutical and biotechnology index declined by 2.62% from November 3 to November 7, underperforming the Shanghai Composite Index by 2.37 percentage points, marking seven consecutive weeks of underperformance [1] - The innovative drug sector (BK1106) fell by 3.51% during the week, while the Hang Seng Healthcare Index dropped by 2.39% and the Hong Kong innovative drug ETF (513120) decreased by 3.92% [1] Industry Commentary - After a strong rally, the innovative drug industry has entered a bubble-popping phase, with a return to rational investment not necessarily being negative for the sector. However, the current market adjustment appears excessive, with leading companies like Kangfang Biotech, Zai Lab, and Kelun-Biotech experiencing declines exceeding 30% [2] - Zai Lab's recent performance has been impacted by two public announcements: disappointing clinical data for its gastric cancer drug Bemarituzumab and a Q3 report showing total revenue of $116 million, a 14% year-on-year increase, but a net loss of $35.96 million, which is a narrowing of losses compared to the previous year. Revenue growth was primarily driven by sales of "Nusinersan" and "Dingyoule," offset by a slowdown in "Zele" sales [2] Short-term Outlook - In the short term, the innovative drug industry is undergoing emotional recovery and valuation reconstruction, with stock volatility heavily influenced by clinical data and earnings guidance. Zai Lab faces short-term emotional pressure due to the termination of a key clinical trial and downward adjustments in performance expectations. However, from a medium to long-term perspective, the innovative logic of the industry remains unchanged, with globally competitive pipeline assets being the core support for company valuations [3] IPO Developments - Nanjing Haina Pharmaceutical Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, with CICC as the sole sponsor. This follows the termination of a major asset restructuring plan in June 2023, where Haina was to be acquired by Chengdu Xian Dao [4] - Haina Pharmaceutical, established in 2001, integrates drug research and manufacturing, providing CXO services and proprietary product pipelines. The company's revenue primarily comes from CXO services, with 398 ongoing CXO projects as of mid-2025 [4] Financial Performance - For 2024, Haina Pharmaceutical projects revenue of 425 million yuan, a year-on-year increase of 3.65%, but a net profit of 53.295 million yuan, reflecting a 27% decline, indicating a situation of "increased revenue but decreased profit." In the first half of the year, both revenue and net profit saw declines of 16.97% and 25.82%, respectively, attributed to a decrease in CRO service income and a 45.8% drop in sales of proprietary drugs [5] Clinical Trial Updates - From November 3 to November 7, the National Medical Products Administration disclosed 110 new clinical trial registrations, with 33 of these being innovative drugs in Phase II or above, primarily covering oncology, immunology, cardiovascular, and psychiatric fields [6] - Four innovative drugs were approved during the week [7] Notable Approvals - The first CAR-T therapy in China, Pucalunase injection (pCAR-19B), was approved for treating pediatric acute B lymphoblastic leukemia patients aged 3 to 21. This drug was previously included in breakthrough therapy and priority review categories [8] - Pucalunase is the fifth CD19 CAR-T product approved in China, following four others from various companies [9]

Core Viewpoint - North Medical Pharmaceutical Co., Ltd. experienced a stock price increase of 5.09%, reaching 6.81 CNY per share, with a trading volume of 495 million CNY and a turnover rate of 12.58%, resulting in a total market capitalization of 4.059 billion CNY [1] Company Overview - North Medical Pharmaceutical, established on May 18, 1993, and listed on June 16, 1997, is located in Yubei District, Chongqing. The company specializes in the research, production, and sales of chemical drug formulations, pharmaceutical distribution, and medical services [1] - The revenue composition of the company includes: pharmaceuticals 34.69%, formulation drugs 34.34%, medical devices and reagents 30.82%, other (supplementary) 0.13%, and sales of goods and materials 0.03% [1] Shareholder Information - Among the top ten circulating shareholders of North Medical Pharmaceutical, one fund from GF Fund Management, the GF Quantitative Multi-Factor Mixed A (005225), has recently entered the list, holding 2.278 million shares, which accounts for 0.38% of the circulating shares. The estimated floating profit today is approximately 751,700 CNY [2] - The GF Quantitative Multi-Factor Mixed A fund was established on March 21, 2018, with a latest scale of 3.618 billion CNY. Year-to-date returns are 50.46%, ranking 1006 out of 8147 in its category; the one-year return is 51.67%, ranking 569 out of 8056; and since inception, the return is 130.92% [2] - The fund managers, Yi Wei and Li Yuxin, have had varying performance during their tenure, with Yi Wei achieving a best fund return of 68.08% and a worst return of -1.82% over 2 years and 130 days, while Li Yuxin achieved a best return of 95.86% and a worst return of 1.14% over 2 years and 21 days [2]

Core Viewpoint - The A-share market is experiencing a strong performance in flu-related stocks, driven by expectations of a flu outbreak in the upcoming winter season [1] Group 1: Market Performance - Flu concept stocks in the A-share market have shown significant gains, with Te Yi Pharmaceutical hitting the daily limit, Tai Long Pharmaceutical and Nanxin Pharmaceutical rising over 7%, Weikang Pharmaceutical increasing over 5%, and Peking University Pharmaceutical up nearly 4% [1] - Yiling Pharmaceutical has also seen an increase of almost 4% [1] Group 2: Health Forecast - The China Center for Disease Control and Prevention (CDC) predicts that the peak of the flu epidemic in China this autumn and winter may occur in mid-December to early January [1] - The CDC is actively monitoring and assessing flu activity across the country, indicating that the overall flu activity in China is currently on the rise [1] - The H3N2 subtype of the influenza virus accounts for over 95% of the cases, with a small presence of H1N1 and B-type influenza viruses circulating simultaneously [1]

Core Viewpoint - The recent criminal detention of Xu Xiren, the chairman and president of Beijing University Pharmaceutical (000788.SZ), has plunged the company and its controlling entity, Southwest Synthetic Pharmaceutical Group, into a public relations crisis [1][2]. Group 1: Company Background and Leadership Changes - Xu Xiren acquired control of Beijing University Pharmaceutical in December 2024 for a symbolic price of 1 yuan, alongside taking over significant debts amounting to 2.392 billion yuan [6]. - Following Xu's takeover, the company's stock price dropped approximately 15% within five trading days, indicating investor skepticism [6]. - The management team underwent significant changes, with multiple high-level executives resigning or being dismissed shortly after Xu's arrival, raising concerns among employees about the stability of the company [9][10]. Group 2: Employee Sentiment and Internal Issues - Employees initially welcomed Xu's leadership but began expressing dissatisfaction due to the removal of benefits and bonuses that were previously provided [8][11]. - The company faced labor disputes, with over ten cases pending since March, reflecting growing unrest among current and retired employees regarding welfare issues [10][11]. - Historical employee placement issues remained unresolved, leading to increased tensions within the workforce, particularly after Xu's controversial decisions regarding employee training and compensation [12][14]. Group 3: Financial and Operational Impact - The company reported a significant increase in net profit of 211% in 2024, but the subsequent leadership changes have raised concerns about future performance [8]. - The "de-BNU" strategy initiated by Xu, which included severing ties with major clients like Peking University International Hospital, is projected to result in a revenue decline of approximately 600 million yuan, representing about 29.13% of the company's recent audited revenue [32]. - In the third quarter, the company experienced a 47.95% year-on-year decline in revenue, further highlighting the operational challenges faced under the new leadership [32].